Corporate Presentation

October 2014

Rev. 20-14

2 | Page

Forward Looking Statement

This presentation contains forward-looking statements. Such forward-looking statements

include but are not limited to that Cesca Therapeutics Inc. will provide unmatched world-

class capability and service to its clients. These statements involve risks and uncertainties

that could cause actual outcomes to differ materially from those contemplated by the

forward-looking statements. A more complete description of risks that could cause actual

events to differ from the outcomes predicted by our forward-looking statements is set forth

under the caption "Risk Factors" in ThermoGenesis annual report on Form 10-K and other

reports we file with the Securities and Exchange Commission from time to time, and you

should consider each of those factors when evaluating the forward-looking statements.

Contact:

Cesca Therapeutics Inc.

http://www.cescatherapeutics.com

Investor Contact: Kirin Smith, ProActive Capital Group

+ 1-646-863-6519, or ir@cescatherapeutics.com

3 | Page

Cesca TherapeuticsCorporate Snapshot

NASDAQ Symbol KOOL

Market Capitalization $51 Million

Shares Outstanding 40.2 Million

Options Outstanding 1.3 Million

Warrants Outstanding 5.1 Million

Stock Price $1.28

Average Trading Volume 80,725

Revenue (TTM) $16 Million

Total Assets $63 Million

Debt None

Corporate Headquarters Rancho Cordova, CA

Clinical Research (GLP Labs) Emeryville, CA

India Operations (CRO & GMP Labs) Gurgaon, India

Stock price and market cap as of October 3, 2014

Financials as of June 30, 2014

4 | Page

Cesca TherapeuticsAn integrated regenerative medicine company

Uniquely positioned to be a best in class Integrated Regenerative Medicine

Company

− Clinical Research Organization (Fortis embedded)

− Proprietary cell formulations

− Devices; patented platform technology

First commercially viable autologous cell therapy

− Safe & Effective; in the regulatory “sweet spot”

− Rapid; 60-90 minute bedside protocol

− Low cost delivery

Opportunity to create substantial shareholder value

− Multiple therapies - 8 pilot & Phase 1b clinical trials

− Unlocks intrinsic value of multiples in regenerative medicine sector

− M&A/bolt on opportunities to help us further fill out our tools capabilities

5 | Page

Cesca TherapeuticsRegenerative Medicine Investor Checklist

• Safe?

• Clinically effective?

• Large markets?

• Regulatory hurdles?

• Cost effective/reimbursable?

6 | Page

Cesca TherapeuticsGo-to-Market Success Formula

Autologous Cells,

Minimally Manipulated

Naturally Safest,

Regulatory Fast track=

Bedside,

Single Procedure 60-90 min

Total Process Control,

+

CT Development Approach CT Product Attributes

Embedded CRO > 600 Trial Patients

+

=+

Low COGS

=+

Proven Curative

Rapid CT Development

& Commercialization

Multiple Shots on Goal

Blockbuster CT Treatments=

SurgWerksTM

1

2

3

7 | Page

Cesca Regulatory “Sweet Spot”Lower risk = speed to market

• IND/BLA• Trial: Three phases• Higher Trial Patient Pop

• IDE/PMA (US)• Trial: only two phases• Lower Trial Patient Pop

8 | Page

Cesca SurgWerksTM

Indication specific POC process control

SurgWerks POC Advantages:

• Integrated Optimized Devices

• “Smart” cell VXP System

• Autologous (safe and fast)

• Data validated

• Highly consistent

• Removes autologous dose variability

• 600 patients treated across eight

clinical indications

9 | Page

Cesca SurgWerksTM

Kit Individualization

• Engineering development collaboration with Cook Medical

• Unique design, pressure regulated

• Licensed device IP and internal method IP

• Proprietary OEM cell harvest technology

• Increases cell recovery

• Maximizes cell viability

• Smart cell vision system – programmable by indication, minimal manipulation

• Infrared optical sensors enable indication specific cell formulations

• Capital purchase & recurring disposable sales

• Strong IP protection (device; method)

• On-board cell diagnostics ensure therapeutic dose

• Proprietary OEM technology (under 2 mins)

• Capital purchase & recurring disposable sales

Harvest

Process

DX

Administer

10 | Page

Fortis PartnershipCRO embedded in New Delhi facility

Cesca is exclusive regenerative medicine

provider to Fortis

• 72 hospitals (6 countries)

• 10,000 inpatient beds

• 15,000 outpatients per day

• Experienced clinical research staff

• 2x as many sites as Kaiser

Physician/patient access

World class clinical facilities and equipment

Lobby partner with government

Embedded CRO Benefits

• Only global cell therapy CRO

• US FDA registered; FDA accepted foreign trial

• Over 600 patients treated

• Control over trial management

• Speed to completion

• 1/5 cost of US/ Europe patient related clinical

trials

Rx Clinical Trial Advantage ($M) Pilot P1/P1b Total

Cesca Investment $2 $7 $9

US Equivalent Investment $17 $28 $45

Non-Dilutive Clinical Trial Funding Benefit $36

11 | Page

Clinical Trial PipelineBlockbuster therapy candidates

$.7B

12 | Page

Clinical Trial Pipeline Major MilestonesSubstantial clinical value drivers

CLI Milestones Calendar Quarter

FDA IDE/PMA Pivotal Trial Submission Q4 2014

Pivotal Phase Completed Late 2016

CLI PMA Approval/Commercialization Early 2017

BMT Milestones Time Period

ABO Mismatch FDA 510(K) Submission Q1 2015

Haplo Pilot Phase Trial Data Published Q3 2015

Haplo Full Market launch/Commercialization 2016

AMI Milestones Time Period

DCGI Phase II Trial Submission Q1 2015

Phase II First Patient Treated Q3 2015

13 | Page

• Primary Mechanism : Paracrine Effect and EPCs– Drives Revascularization

(Collaterals)

• Implanted cells migrate to ischemic regions

• Implanted cells secrete cytokines for mobilization of local tissue stem cells

• Implanted cells secrete cytokines for mobilization of bone marrow stem cells

– Revascularization drives regeneration

Clinical Trial Pipeline Underlying Science (Mechanism of Actions)

Sen et al, Clinical Science (2011) 120; 263-283

Asahara T et al. Science. 1997: 275:964-7Takahashi T et al. Nature Med. 1990:5:434-8

14 | Page

Clinical Trial Pipeline Confirming Our MOA with Human Data

Critical Limb IschemiaIM Delivery of BMMNCs : > 21 Day Life but < 28 Days BMMNC (with EPCs) Initiate Tube Formation

Odaka et al (2011) PLoS One. 6(10):e25487

Acute Myocardial Infarction

Gnecchi et al (2008). Circ Res. 103: 1204-1219

15 | Page

Critical Limb IschemiaCompelling clinical vascular results

All patients “no option” and near term

leg amputation recommended

12 Month F/U Data

• Major Amputation Free Rate post

SurgWerks™ Therapy = 82.4%

• Reduction in VAS Pain Score

from 7.8±0.97 to 0.2±0.58

• Improvement in 6 minute walk

test from 14.5m to 157m

• N=17 patients

Major RevascularizationTrial Results

CompletedPhase I/II

IDE PMA

Pivotal

Submit Q4 2014 /

First Subject March

2015

Day 0 Day 365

16 | Page

• LVEF improvement = from 36%

to 60%

• Stroke volume improvement =

from 39.7cc to 80cc

• Scar remains 11% of total heart

mass

• Normal life resumed

• N=1 patient (24 Mo F/U)

Cardiac Tissue RepairTrial Results

Acute Myocardial InfarctionCompelling clinical cardiac results

PilotCompleted

Ph II

Submit Q1 2015Begin June Qtr. 2015 (DCGI)

17 | Page

Bone Marrow TransplantAutomating clinical major mismatch & haploidentical transplant

Improves Pediatric BMT (40% are mismatched)

• High - CD34 recoveries = 77.7%

• Low - hematocrit <12%

• Faster - Neutrophil engraftment = Day 18

• Faster - Platelet engraftment = Day 35

Haploidentical Clinical Results

Major ABO Clinical Results

Faster,Lower Cost,

Higher Cell Recovery

510(k) March Qtr. 2015

6,000 = new patients WW

$1,500 = Price of treatment

$9 M = Addressable market

• Reduces Expensive Reagent Usage

• Enables Cell Washing

6,000 = new patients India

$25,000 = Price of treatment

$150 M = Addressable market

Enabling 6k annual patient market in India

Plan to commercialize globally

Phase I/II September Qtr. 2015

18 | Page

Cesca SurgwerksTM

Sustainable differentiation

Significant commercial experience, proven technical reliability

• Over 20,000 patients treated @ POC with Cesca Cell Technologies

• Over 600,000 cord samples processed (laboratory)

• Near six-sigma disposable quality levels

Clinically validated, proprietary protocols & method patents

• Proprietary, smart platforms

• Proprietary cell formulations addressing multiple disease indications

• Pioneering with regulatory strategy to be first cell therapy in a box

IP Suite (device and algorithm patents)

• 43 Design and device patents

• Three protocol provisional patents (6 indications)

• 8 pilot & phase 1b clinical trials

• 7 clinical algorithms

19 | Page

Cesca TherapeuticsMarket Cap Snapshot

Cell Therapy Peer Company TCKR Market Capitalization (000’S)

Aastrom Biosciences Inc. ASTM $66,000

Athersys ATHX $102,000

BioTime, Inc. BTX $239,000

Cytomedix, Inc. CMXI $45,000

Neuralstem, Inc. CUR $284,000

Cytori Therapeutics Inc. CYTX $52,000

Dendreon Corporation DNDN $212,000

NeoStem Inc. NBS $184,000

Osiris Therapeutics, Inc. OSIR $426,000

Pluristem Therapeutics Inc. PSTI $208,000

StemCells Inc. STEM $87,000

Average Market Cap $173,000

Cesca Therapeutics KOOL $52,000As of October 6, 2014

20 | Page

Cesca TherapeuticsRegenerative Medicine Investor Checklist

Safe - Autologous

Clinically effective - Yes

Large markets - Multiple

Regulatory hurdles - Lower

Cost effective – Yes

Reimbursable – Well positioned

21 | Page

Management Highlights

Chief Executive Officer & Director

Matthew T. Plavan - Leading Cesca since 2012, effected merger with TotipotentRX in 2014, served as COO and EVP

Business Development, 2008-2010, CFO from 2005. Prior experience includes McKesson/Ernst & Young.

President & Director

Kenneth L. Harris - Joined Cesca in February 2014 pursuant to merger. Prior experience includes Chairman and CEO of

TotipotentRX /MK Alliance, Inc, and Corporate Senior Vice President and Global President of Biosciences of Pall Corporation.

Chief Financial Officer

Dan T. Bessey - Joined Cesca in March 2013. Prior experience includes CFO of SureWest Communications and Vice

President of Finance, Controller and Director of Corporate Finance.

Chief Biologist

Mitch Sivilotti – Joined Cesca in February 2014 pursuant to merger. Prior experience includes President, Director and Chief

Biologist of TotipotentRX/MK Alliance, Inc. and Pall Corporation.

VP, Quality & Regulatory Affairs

Raymond DeGrella – Consulted for Cesca as VP of Quality and Management Representative since 2012. In March 2014

assumed current role. Former experience includes Vice President Advanced Supply Chain of Beckman Coulter, and Abbott

Laboratories.

VP, OperationsKen Pappa – Joined Cesca in April 2006 as Director of Finance and has held several managerial roles until October 2012

when he took on his current role. Prior experience includes Manufacturing Controller and Senior Operations Manager for

Hewlett Packard-Agilent Technologies.

Thank you